Therapeutic targeting of GDF11 in muscle atrophy: Insights and strategies.
Abstract
The exploration of novel therapeutic avenues for skeletal muscle atrophy is imperative due to its significant health impact. Recent studies have spotlighted growth differentiation factor 11 (GDF11), a TGFβ superfamily member, for its rejuvenating role in reversing age-related tissue dysfunction. This review synthesizes current findings on GDF11, elucidating its distinct biological functions and the ongoing debates regarding its efficacy in muscle homeostasis. By addressing discrepancies in current research outcomes and its ambiguous role due to its homological identity to myostatin, a negative regulator of muscle mass, this review aims to clarify the role of GDF11 in muscle homeostasis and its potential as a therapeutic target for muscle atrophy. Through a thorough examination of GDF11's mechanisms and effects, this review provides insights that could pave the way for innovative treatments for muscle atrophy, emphasizing the need and strategies to boost endogenous GDF11 levels for therapeutic potential.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper discusses GDF11's role in muscle atrophy, which is related to age-related tissue dysfunction, thus addressing a potential therapeutic target that could influence longevity. However, while it provides a synthesis of current findings and insights into GDF11's mechanisms, the contributions appear to be solid but limited in scope, focusing more on clarifying existing debates rather than presenting groundbreaking findings.
Author of this paper? Send a correction.